// App-Quantinova.ai

9 : Final results from ACIS, a randomized, placebo (PBO)-controlled double-blind phase 3 study of apalutamide (APA) and abiraterone acetate plus prednisone (AAP) versus AAP in patients (pts) with chemo-naive metastatic castration-resistant prostate cancer (mCRPC).

Researchers

Presenter

  • Dana E. Rathkopf

Principal Investigators

  • Eleni Efstathiou

  • Gerhardt Attard

  • Thomas W. Flaig

  • Fabio Andre Franke

  • Oscar B. Goodman

  • Stephane Oudard

  • Thomas Steuber

  • Hiroyoshi Suzuki

  • Daphne Wu

  • Kesav Yeruva

  • Peter De Porre

  • Sabine Doris Brookman-May

  • Susan Li

  • Jinhui Li

  • Suneel Mundle

  • Sharon Anne McCarthy

  • Fred Saad

Medical Centers

  • Memorial Sloan Kettering Cancer Center, Port Washington, NY

  • The University of Texas MD Anderson Cancer Canter, Houston, TX

  • Kings College London, London, United Kingdom

  • University of Colorado Cancer Center, Aurora, CO

  • Oncosite Centro de Pesquisa Clínica, Ijuí, Brazil

  • Comprehensive Cancer Centers of Nevada, Las Vegas, NV

  • Georges Pompidou Hospital, University René Descartes, Paris, France

  • University Hospital Eppendorf Frauenklinik, Hamburg, Germany

  • Toho University Sakura Medical C, Kashiwa-City, Japan

  • Janssen Research & Development, Los Angeles, CA

  • Janssen Research & Development, Beerse, Belgium

  • Janssen Oncology, Los Angeles, CA

  • Janssen Research and Development, LLC, Spring House, PA

  • Janssen Research & Development, San Diego, CA

  • Janssen Research & Development, LLC, Raritan, NJ

  • Centre Hospitalier de LUniversite de Montreal (CHUM), Montreal, QC, Canada

Locations

  • United States

  • United Kingdom

  • Brazil

  • France

  • Germany

  • Japan

  • Belgium

  • Canada

Companies

  • N/A

Study Components

Therapeutic Area

  • Oncology (ONC)

  • Urology

Disease

  • Metastatic castration-resistant prostate cancer

Biomarkers

  • Prostate specific antigen

Drug/Treatment

  • CB-7598

  • Prednisone

  • Androgen Tear

  • Epimorph

Outcome

  • N/A

Study Design

  • Randomized

  • Placebo Control

  • Double Blind/Blinded

  • Controlled

Phase

  • III

Study Id's

  • NCT02257736

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved